Checkpoint Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Common Stock Warrant Liabilities (Tables)

Common Stock Warrant Liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Common Stock Warrant Liabilities

Summary of common stock warrant liabilities


		Warrant
		Liabilities
Common Stock Warrant liabilities at December 31, 2021		$	—
Issuance of December 2022 Common Stock Warrants			7,640
Issuance of December 2022 Placement Agent Warrants			278
Change in fair value of Common Stock Warrant liabilities			3,252
Common Stock Warrant liabilities at December 31, 2022		$	11,170
Change in fair value of Common Stock Warrant liabilities			(7,924)
Exercise of December 2022 Common Stock Warrants			(3,121)
Common Stock Warrant liabilities at December 31, 2023		$	125

Summary of the weighted average (in aggregate) significant unobservable inputs used in measuring the warrant liability that are categorized within Level 3 of the fair value hierarchy


		October 4,			December 31,
Series A Warrants		2023			2022
Exercise price		$	1.76		$	4.08
Volatility			91.4	%		89.4	%
Expected life			4.2			5.0
Risk-free rate			4.7	%		4.0	%
Dividend yield			—			—


		October 4,			December 31,
Series B Warrants		2023			2022
Exercise price		$	1.76		$	4.08
Volatility			99.6	%		82.4	%
Expected life			0.7			1.5
Risk-free rate			5.4	%		4.7	%
Dividend yield			—			—


		December 31,			December 31,
Placement Agent Warrants		2023			2022
Exercise price		$	5.41		$	5.41
Volatility			96.4	%		89.4	%
Expected life			4.0			5.0
Risk-free rate			3.8	%		4.0	%
Dividend yield			—			—